Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Zixi Wang, Yurou Xing, Bingjie Li, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer
Vincent D. de Jager, Wim Timens, Arnaud Bayle, et al.
The Lancet Regional Health - Europe (2024) Vol. 38, pp. 100839-100839
Open Access | Times Cited: 26
Cutting-Edge Therapies for Lung Cancer
Anita Silas La’ah, Shih‐Hwa Chiou
Cells (2024) Vol. 13, Iss. 5, pp. 436-436
Open Access | Times Cited: 9
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 8
Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation
Xiaohui Du, Congcong Zhang, Ying Li, et al.
MedComm – Oncology (2025) Vol. 4, Iss. 1
Open Access | Times Cited: 1
Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer
Xin Zhang, Xuemei Wang, Lijian Hou, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 17
Sunvozertinib: First Approval
Sohita Dhillon
Drugs (2023) Vol. 83, Iss. 17, pp. 1629-1634
Open Access | Times Cited: 14
Cutting-Edge Therapies for Lung Cancer
Anita Silas La’ah, Shih-Hwa Chiou
(2024)
Open Access | Times Cited: 5
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Lorena Ostios-García, Daniel Martínez-Pérez, Beatriz Castelo, et al.
Cancer and Metastasis Reviews (2024) Vol. 43, Iss. 4, pp. 1561-1571
Open Access | Times Cited: 4
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial
Yixian Liu, Xiaoyu Li, Mengyu Zhang, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 515-524
Open Access
Structure-Based Design of New LSD1/EGFRL858R/T790M Dual Inhibitors for Treating EGFR Mutant NSCLC Cancers
Jingya Zhang, Pengxing He, Wenwen Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Biomarkers in lung cancer treatment
Rekha Thiruvengadam, Carmelin Durai Singh, Benod Kumar Kondapavuluri, et al.
Clinica Chimica Acta (2025), pp. 120267-120267
Closed Access
Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatment
B. Munárriz, Sam Khan, Y Q Li, et al.
Cancer (2025) Vol. 131, Iss. S1
Closed Access
Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19
Aroona Razzaq, Cyrollah Disoma, Yuzheng Zhou, et al.
Reviews in Medical Virology (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 10
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression
Marzia Del Re, Giovanna Irene Luculli, Iacopo Petrini, et al.
Translational Oncology (2024) Vol. 41, pp. 101869-101869
Open Access | Times Cited: 3
MET alterations in advanced non-small cell lung cancer
Gabriel Cavalcante Lima Chagas, Amanda Ribeiro Rangel, Badi El Osta
Current Problems in Cancer (2024) Vol. 49, pp. 101075-101075
Closed Access | Times Cited: 3
Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer
Motohiro Izumi, Daniel B. Costa, Susumu Kobayashi
Lung Cancer (2024) Vol. 194, pp. 107885-107885
Closed Access | Times Cited: 3
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges
A. Raja, Abhishek Kasana, Vaishali Verma
Molecular Biotechnology (2024)
Closed Access | Times Cited: 3
Expression and Functional Analysis of Immuno-Micro-RNAs mir-146a and mir-326 in Colorectal Cancer
Ovidiu Farc, Liviuța Budișan, Florin Zaharie, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 7065-7085
Open Access | Times Cited: 2
A graphSAGE discovers synergistic combinations of Gefitinib, paclitaxel, and Icotinib for Lung adenocarcinoma management by targeting human genes and proteins: the RAIN protocol
Sogand Sadeghi, Ali A. Kiaei, Mahnaz Boush, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Adiponectin Receptor Agonist AdipoRon Inhibits Proliferation and Drives Glycolytic Dependence in Non-Small-Cell Lung Cancer Cells
Sanober Kafeel, Angela Ragone, Alessia Salzillo, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2633-2633
Open Access | Times Cited: 1
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, et al.
Journal of Pathology and Translational Medicine (2024) Vol. 58, Iss. 4, pp. 147-164
Open Access | Times Cited: 1
Molecular landscape of lung cancer: insights into therapeutic targets and clinical outcomes
Saloni Mangal, Abhijit Debnath, Rupa Mazumder, et al.
All Life (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Add fuel to the fire: Inflammation and immune response in lung cancer combined with COVID-19
Yanling Ai, Hengyi Wang, Qiao Zheng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Mathematical Modeling Support for Lung Cancer Therapy—A Short Review
Jarosław Śmieja
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14516-14516
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top